The Bott Cancer Center at Holy Redeemer Hospital is proud to provide advanced cancer care to our patients and community by offering a variety of cancer clinical trials. Cancer clinical trials are research studies in which people and health care professionals work together to improve cancer care. They provide answers to scientific questions and help to find better ways to prevent, diagnose, or treat cancer. People who choose to take part in cancer clinical trials have an opportunity to contribute to the advancement of cancer care, while receiving the latest treatment options from clinical experts.
Holy Redeemer’s Institutional Review Board (IRB) supports the cancer clinical trials program by reviewing each clinical trial to ensure the study is conducted fairly and the rights and welfare of volunteer participants are protected. Holy Redeemer’s IRB is made up of doctors, researchers, nurses, pharmacists, local leaders, and other members of the community who are committed to our goal to provide the highest quality of care to our community.
As a member of the Penn Cancer Network, Holy Redeemer is able to provide access to trials sponsored by the National Cancer Institute. In addition, through the membership with the Abramson Cancer Center at the University of Pennsylvania, we are able to provide access to select National Institute of Health supported clinical trials that have been developed by researchers at Penn.
Clinical trials are completely voluntary; participation is a personal decision that should be made by each individual in conjunction with their physician and family. Please speak with your doctor to find out if a clinical trial is right for you or your loved one.
If you are interested in learning more about clinical trials at the Bott Cancer Center, please speak with your doctor or call our Clinical Trials Office at 215-938-3551.
Holy Redeemer Hospital Clinical Trials
Collapse all | Expand all
NSABP B43: A Phase III Clinical Trial comparing Trastuzumab given concurrently with Radiation Therapy and Radiation Therapy alone for Women with HER2 Positive DCIS Resected by lumpectomy.
This study compares the effects of adding Trastuzumab (also called Herceptin) to breast radiation alone. Breast radiation is the “usual” or standard treatment for DCIS.
RTOG 1005: A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation plus concurrent Boost vs Standard Whole Breast Irradiation plus Sequential Boost for Early Stage Breast Cancer.
This study compares the standard dose of radiation therapy to the whole breast followed by additional radiation (boost) to the area of surgery vs a higher daily dose of radiation to the whole breast and the “boost” on the same days, but in a shorter number of daily treatments.
ECOG 2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in patients with Metastatic Breast Cancer.
This study compares a different treatment approach for breast cancer, which has spread beyond the breast to other parts of the body with the standard or usual treatment.
Outcomes Study: A clinical trial gathering prospective data on the side effects and treatment related outcomes in women treated with radiation for Localized Breast Cancer.
This study is being done to gather and monitor data on women receiving radiation therapy for breast cancer to look at the side effects and responses to treatment in the future.
Participate in the WISER Survivor Study: The WISER Survivor project is an approximately 14-month weight loss and exercise study for sedentary breast cancer survivors who are overweight and who have symptoms or a history of breast cancer related lymphedema. This study will examine the effect exercise and/or weight loss has on lymphedema, breast cancer recurrence and quality of life—Holy Redeemer is a study site. To learn more, click here.
CALGB 30610: A Phase III Comparison of Thoracic Radiotherapy Regimens in patients with Limited Small Cell Lung Cancer also receiving Cisplatin and Etoposide.
This study looks at 2 different ways to give radiation therapy for patients with limited stage small cell lung cancer that has not been detected outside the chest.
Lung Cancer Screening Program Using Low Dose CT Scan with Prospective Patient Outcome Data Collection: The National Cancer Institute (NCI) conducted a large national lung screening trial (NLST), which showed a benefit in detecting lung cancer earlier in heavy smokers using LDCT. Essentially, it comes down to how long and how much you have smoked in your lifetime. At this time, most insurance does not cover this scan and there is a cost ($289); however, this test can be very valuable in detecting early stage lung cancer, when it is most treatable.
For more information, call 215-938-LUNG
or click here
For more information on Clinical Trials, please visit the following websites:
National Cancer Institute